Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.

Volltext-Artikel, E-Books und Literaturhinweise aus dem EBSCO Discovery Service

"Artikel & mehr" berücksichtigt nur einen Teil der für die Bibliothek der Frankfurt UAS verfügbaren Datenbanken. Zur Übersicht in DBIS

Ergebnis verändern

einschränken: Volltextzugriff; Academic (peer-reviewed) journals
erweitern: Auch Volltexte der Artikel durchsuchen; Verwandte Themen suchen

Publikationstyp

Thema

erschienen in

Verlag

Geographic terms

Sprache

Datenbank

Erscheinungsjahr

Von:

Bis:

Treffer 1 - 25 von 160, Suchdauer: 0.83s

12 3 4 5 6 7 weiter »

1
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial

von Lorusso, Domenica ; Gladieff, Laurence ; O'Malley, David M ; et al.

In The Lancet 18-24 April 2026 407(10538):1513-1524
- View full text via DOI
Merkliste

2
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

von Olawaiye, Alexander B ; Gladieff, Laurence ; O'Malley, David M ; et al.

In The Lancet 21-27 June 2025 405(10496):2205-2216
- View full text via DOI
Merkliste

3
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.

von Banerjee, S ; Giannone, G ; Clamp, AR ; et al.

Schlagworte: United States
- View full text via BASE
Merkliste

4
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial

von Clamp AR ; James EC ; McNeish IA ; et al.

The Lancet Oncology, July 2022
- View full text via BASE
Merkliste

5
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.

von Clamp, AR ; James, EC ; McNeish, IA ; et al.

Schlagworte: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Ovarian Epithelial; Fallopian Tubes; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel
- View full text via BASE
Merkliste

6
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety

von Oaknin, A ; Oza, AM ; Lorusso, D ; et al.

Cancer Medicine (2021) (In press).

Schlagworte: Clinical trials; gyecological oncology; medical oncology; target therapy; women's cancer
- View full text via BASE
Merkliste

7
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

von Clamp, AR ; Lorusso, D ; Oza, AM ; et al.

International Journal of Gynecological Cancer (2021) (In press).
- View full text via BASE
Merkliste

8
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial

von Morgan, RD ; McNeish, IA ; Cook, AD ; et al.

The Lancet Oncology , 22 (2) pp. 277-288. (2021)
- View full text via BASE
Merkliste

9
2 Exploratory analysis of postprogression and patient-centered outcomes in ariel3: a phase 3, randomized, placebo-controlled study of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma

von Coleman, R ; Oza, AM ; Lorusso, D ; et al.

Plenary sessions ; page A1.2-A2
- View full text via BASE
Merkliste

10
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial

von Blagden SP ; Cook AD ; Poole C ; et al.

The Lancet Oncology, July 2020
- View full text via BASE
Merkliste

11
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.

von Clamp, AR
- View full text via BASE
Merkliste

12
Ciliates — Protists with complex morphologies and ambiguous early fossil record

von Dunthorn, Micah ; Lipps, Jere H. ; Dolan, John R. ; et al.

In Marine Micropaleontology September 2015 119:1-6
- View full text via DOI
Merkliste

13
A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity

von Nelson, L ; Tighe, A ; Golder, A ; et al.
- View full text via BASE
Merkliste

14
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial

von Blagden, S ; Cook, AD ; Poole, C ; et al.
- View full text via BASE
Merkliste

15
Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial

von James, EC ; Dunn, D ; Cook, AD ; et al.

Trials , 21 (1) , Article 802. (2020)

Schlagworte: Adverse events; Safety data; Serious adverse events
- View full text via BASE
Merkliste

16
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

von Colombo, N ; Oza, AM ; Lorusso, D ; et al.

Gynecologic Oncology (2020) (In press).

Schlagworte: Elderly patients; Maintenance; Ovarian cancer; PARP inhibitor; Rucaparib
- View full text via BASE
Merkliste

17
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma

von Oza, AM ; Lorusso, D ; Aghajanian, C ; et al.

Journal of Clinical Oncology (2020) (In press).
- View full text via BASE
Merkliste

18
Progression-free survival in the ICON8 trial – Authors' reply

von James, EC ; McNeish, IA ; Cook, AD ; et al.

The Lancet , 396 (10253) p. 757. (2020)
- View full text via BASE
Merkliste

19
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial

von Blagden, SP ; Cook, AD ; Poole, C ; et al.

The Lancet Oncology , 21 (7) pp. 969-977. (2020)
- View full text via BASE
Merkliste

20
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial

von Ledermann, JA ; Oza, AM ; Lorusso, D ; et al.

Lancet Oncology , 21 (5) pp. 710-722. (2020)
- View full text via BASE
Merkliste

21
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial

von Morgan, RD ; McNeish, IA ; Cook, AD ; et al.

288 ; 277

Schlagworte: Oncology & Carcinogenesis; 1112 Oncology and Carcinogenesis
- View full text via BASE
Merkliste

22
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

von Clamp, AR ; James, EC ; McNeish, IA ; et al.

The Lancet (2019)
- View full text via BASE
Merkliste

23
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study

von Morgan, RD ; Clamp, AR ; Barnes, BM ; et al.

Schlagworte: BRCA1 Protein; BRCA2 Protein; Homologous recombination; Ovarian Cancer
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

24
Improved survival from ovarian cancer in patients treated in Phase III trial active cancer centres in the UK

von Khoja, Leila ; Nolan, K ; Mekki, R ; et al.

Khoja, L, Nolan, K, Mekki, R, Milani, A, Mescallado, N, Ashcroft, L, Hasan, J, Edmondson, R, Winter-Roach, B, Kitchener, H, Mould, T, Hutson, R, Hall, G, Clamp, AR, Perren, T, Ledermann, J & Jayson, G 2016, 'Improved survival from ovarian cancer in patients treated in Phase III trial active cancer centres in the UK', Clinical Oncology. https://doi.org/10.1016/j.clon.2016.06.011

Schlagworte: ResearchInstitutes_Networks_Beacons/mcrc; name=Manchester Cancer Research Centre
- View full text via BASE
Merkliste

25
Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK

von Khoja, L ; Nolan, K ; Mekki, R ; et al.

Clinical Oncology , 28 (12) pp. 760-765. (2016)

Schlagworte: Cancer centre; clinical trial; ovarian cancer; prognosis; survival outcomes; UK
- View full text via BASE
Merkliste

12 3 4 5 6 7 weiter »

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag